{"doi":"10.1093/sleep/zsaf024","title":"Way to go with OSA biomarkers","abstract":"In this issue of SLEEP, the Research Report by Gottfried et al. [1] describes associations between obstructive sleep apnea (OSA) metrics and biomarkers assigned to alveolar epithelial cell injury (surfactant protein D), endothelial inflammation (E-selectin, angiopoietin-2), and angiogenesis (Tie2, VEGF-A, angiopoietin-2). The population was the NIH-sponsored Mult-Ethnic Study of Atherosclerosis (MESA) participants, a feature cohort in sleep medicine reports on OSA epidemiology, metrics, and outcomes. Biomarkers were measured using immunoassays, and the associations with OSA severity were tested using multiple clinical features of the polysomnogram, including all measures of the apnea–hypopnea index (AHI), sleep-related hypoxemia, and hypoxic burden. The study discovered significant associations between OSA severity and higher levels of E-selectin, sTie2, and VEGF-A. Specifically, higher AHI scores were associated with higher levels of E-selectin, sTie2, and VEGF-A. A greater percentage of time spent with oxygen saturation below 90% was significantly associated with E-selectin and angiopoietin-2. Interestingly, while obesity (body mass index) diminished the strength of some of these associations, E-selectin remained strongly linked to OSA severity, particularly in terms of nocturnal hypoxemia. These associations remind us of a prior report [2], which found OSA patients had a stronger relationship for this marker compared to patients without OSA in relation to developing incident cardiovascular disease. MESA is a community-based cohort, rather than a population recruited from sleep medicine clinics making the findings generalizable to a broader population; the study’s cross-sectional nature means that it cannot establish causality or prognosis for patients in the clinic.","journal":"SLEEP","year":2025,"id":551333,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7661,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":423974,"name":"Kingman P. Strohl","orcid":"0000-0001-7740-9013","position":1,"is_corresponding":false},{"id":1447475,"name":"Priya V Borker","orcid":null,"position":0,"is_corresponding":true}],"reference_count":11,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:54:25.065895Z","pmid":"39868524","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}